Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Related Articles by Review for PubMed (Select 23241893)

1.

Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.

Schmiedel BJ, Nuebling T, Steinbacher J, Malinovska A, Wende CM, Azuma M, Schneider P, Grosse-Hovest L, Salih HR.

J Immunol. 2013 Jan 15;190(2):821-31. doi: 10.4049/jimmunol.1201792. Epub 2012 Dec 14.

2.

Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.

Chen T, Feng X.

Assay Drug Dev Technol. 2006 Aug;4(4):473-82. Review.

PMID:
16945019
3.

[Control of bone resorption by RANKL-RANK system].

Harada S, Takahashi N.

Clin Calcium. 2011 Aug;21(8):1121-30. doi: CliCa110811211130. Review. Japanese.

PMID:
21814016
4.
5.

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R.

Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. Review.

PMID:
22543469
7.

RANKL inhibition: from mice to men (and women).

Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ.

Adv Exp Med Biol. 2007;602:143-50. Review.

PMID:
17966399
8.

Biology of RANK, RANKL, and osteoprotegerin.

Boyce BF, Xing L.

Arthritis Res Ther. 2007;9 Suppl 1:S1. Review.

9.

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE.

J Mol Med (Berl). 2001 Jun;79(5-6):243-53. Review.

PMID:
11485016
10.

RANKL/RANK-beyond bones.

Hanada R, Hanada T, Sigl V, Schramek D, Penninger JM.

J Mol Med (Berl). 2011 Jul;89(7):647-56. doi: 10.1007/s00109-011-0749-z. Epub 2011 Mar 29. Review.

PMID:
21445556
11.

Targeting RANKL in breast cancer: bone metastasis and beyond.

Azim H, Azim HA Jr.

Expert Rev Anticancer Ther. 2013 Feb;13(2):195-201. doi: 10.1586/era.12.177. Review.

PMID:
23406560
12.

Role of denosumab in prostate cancer.

Helo S, Manger JP, Krupski TL.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):231-6. doi: 10.1038/pcan.2012.2. Epub 2012 Feb 28. Review.

PMID:
22370723
13.

Outflanking RANK with a designer antagonist cytokine.

Ou-Yang CW, Siegel RM.

Sci Signal. 2014 Aug 19;7(339):pe20. doi: 10.1126/scisignal.2005674. Review.

PMID:
25140052
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk